Introduction
============

Retinitis pigmentosa (RP, OMIM [268000](http://omim.org/entry/268000)) is the most common and highly heterogeneous genetic group of hereditary retinal degeneration diseases, affecting one in about 3,500--5,000 individuals worldwide \[[@r1]-[@r3]\]. So far, mutations in over 60 genes have been reported to be responsible for about half of nonsyndromic RP \[[@r4]-[@r6]\]. Phenotypic and molecular genetic overlap has been observed in different forms of retinal degeneration \[[@r7],[@r8]\]; for example, RP might be the main sign of syndromic RP or other related diseases \[[@r9]-[@r11]\]. Mutations in a few genes have been shown to cause different forms of retinal dystrophy \[[@r7]\], while a few genes originally held responsible for other forms of retinal dystrophy have been found to cause RP as well \[[@r12]\]. Systematic analysis of all genes responsible for other forms of retinal dystrophy in patients with RP is limited, especially in Chinese cohorts \[[@r13],[@r14]\]. Therefore, systemic evaluation of the frequency of mutations in all genes responsible for other forms of retinal dystrophy, apart from known RP genes, would be valuable.

Our previous whole exome sequencing study detected potential pathogenic mutations in 73 known genes in 86 of 157 patients with RP \[[@r15]-[@r17]\]. Due to the highly heterogeneous and genetically and clinically complicated features of RP, mutations in the genes related to more severe or syndromic diseases might be ignored, and mutations in previously analyzed genes might be mistakenly used in molecular diagnosis and clinical evaluation. Therefore, it might be interested to know if mutations in genes associated with other forms of retinal dystrophy may also contribute to RP. In the present study, variants in 129 genes responsible for other forms of retinal dystrophy were analyzed based on the exome data set of the same cohort of 157 patients.

Methods
=======

This study conformed to the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of the Zhongshan Ophthalmic Center. Written informed consent was obtained from the participants or their guardians before the collection of their clinical data and preparation of genomic DNA from their peripheral venous leukocytes. The cohort of 157 probands with RP, including 34 autosomal dominant RP, 27 autosomal recessive RP, 10 X-linked RP, and 86 sporadic RP, were the same as described in our previous study \[[@r15]\]. All 157 probands were initially diagnosed as non-syndromic RP. The criteria for defining RP in the families was based on the oral descriptions of the features by the probands and their family members, such as poor vision and night blindness, or the clinical examination of the other RP patients; the clinical features of RP patients were similar to those of the probands and included attenuated retinal artery and pigment abnormality in the mid-peripheral retina. Whole exome sequencing was performed by the NimbleGen SeqCap EZ Exome (44M) array and Illumina Genome Analyzer II platform with a sequencing depth of 60-fold, as described previously \[[@r15],[@r18],[@r19]\].

A total of 221 genes were listed in [RetNet](https://sph.uth.edu/Retnet/)[,]{.ul} accessed on January 27, 2014. Of these, 60 of the 62 genes with known association with RP had been analyzed in our previous study; the remaining two were not analyzed because *EMC1* was not captured and *FSCN2* (MIM: [607643](http://omim.org/entry/607643)) was confirmed not to be an RP gene \[[@r20]\]. Of the remaining 159 genes, the following 30 were not included in this study: 1) nine genes associated with age-related macular degeneration, since no evidence shows that these genes were associated with monogenetic retinal diseases; 2) seven genes encoded by mitochondrial DNA that were not captured by the NimbleGen SeqCap EZ Exome (44M) array; and 3) *CHM* (MIM: [300390](http://omim.org/entry/300390)*)*, *CYP4V2* (MIM: [608614](http://omim.org/entry/608614)), and 12 genes associated with Leber congenital amaurosis (LCA) that were independently analyzed in our previous studies \[[@r16],[@r17],[@r21]\]. Ultimately, 129 genes were included in this study. All genes screened in the earlier studies and in the current study are listed in Appendix 1.

Variants in the 129 genes were selected based on the data set from whole exome sequencing. Candidate variants were filtered out with the following multiple-step bioinformatics analysis: 1) the SNPs and short indels in the exome region were filtered against data from dbSNP132, the 1000 Genome Project, HapMap, the YH project, and the Exome Variant Server, removing minor allele frequency (MAF) values that were greater than 0.01, the frequency based on the incidence of RP (1/4000), and the fraction of heterozygotes in Hardy--Weinberg equilibrium; 2) excluded non-coding variants without altering splicing sites predicted by [BDGP](http://www.fruitfly.org/seq_tools/splice.html); 3) excluded the synonymous variants without altering splicing sites in the genes; 4) excluded missense variants predicted to be benign by both [Polyphen-2](http://genetics.bwh.harvard.edu/pph2/) and [SIFT](http://sift.jcvi.org) in autosomal dominant and X-linked genes; and 5) compared with the whole exome sequencing data of 633 individuals in ethnic-matched regions without retinal degeneration.

Sanger sequencing was used to confirm the candidate variants with primer pairs targeting the fragments encompassing the candidate variants. Primers (Appendix 2) were designed using [Primer3](http://primer3.ut.ee/) \[[@r22]\]. The procedures used for amplification, sequencing, and analysis of the target fragments were as previously described \[[@r18],[@r19]\]. Segregation analysis of potential pathogenic variants were performed in available family members. Candidate causative mutations were validated in 192 normal Chinese individuals.

Results
=======

Multiple-step bioinformatics analysis was used to select 90 candidate variants from the 129 genes from the whole exome sequencing of the 157 patients. Of the 90 variants, 83 (92%) were confirmed by Sanger sequencing, while the other 7 (8%) with the low sequencing depth were false-positives. Of the 83, 76 (Appendix 3) were considered as unlikely causes of RP for the following reasons: 1) mutations that are more likely to be pathogenic have already been detected in one of the 72 genes related to RP and LCA or *CHM* in our previous studies \[[@r15]-[@r17]\]; 2) the genotype did not match the patterns of inheritance; 3) the variants did not segregate with the disease; 4) the variants were found in controls or in the 1000 Genome/Exome Variant Server database with a frequency higher than the prevalence rate of RP as causative mutations; 5) the variants were unlikely or less likely to be pathogenic mutations based on previous reports; 6) the phenotype did not match the genotype; and 7) the other allele for compound heterozygous variants if one of them was confirmed to be a false-positive. The remaining seven variants involved three genes: *BBS2* (MIM: [606151](http://omim.org/entry/606151)), *INPP5E* (MIM: [613037](http://omim.org/entry/613037)), and *CACNA1F* (MIM: [300110](http://omim.org/entry/300110)); these were considered to be potentially causative in five patients ([Figure 1](#f1){ref-type="fig"} and [Table 1](#t1){ref-type="table"}), including three patients with homozygous (1) or compound heterozygous (2) mutations in genes associated with an autosomal recessive trait, and two patients with hemizygous mutation in genes associated with an X-linked trait. Limited cosegregation analysis and family structure did not reject the association of the mutations with RP ([Figure 1](#f1){ref-type="fig"}). The carriers with the heterozygous mutant alleles were evaluated as asymptomatic for the disease through follow-up examinations and revisits by phone calls. All 7 mutations were absent in the 192 normal individuals ([Table 1](#t1){ref-type="table"}).

![Pedigrees of the five families with mutations and sequence chromatography. The family members and their corresponding mutations are shown just above the pedigrees (+: wild-type allele). Sequence changes that were detected in the patients are shown (left column) and compared with corresponding normal sequences (right column).](mv-v21-477-f1){#f1}

###### The seven potential pathogenic variants from genes associated with other forms of retinal dystrophy in the five of 157 patients with retinitis pigmentosa.

  **Gene**    **Inheri-tance**   **Patient ID**   **Chromo-some**   **Start position**   **Nucleotide change**   **Amino acid change**   **State**   **Computational prediction**   **Allele frequency in**   **Reported**                                          
  ----------- ------------------ ---------------- ----------------- -------------------- ----------------------- ----------------------- ----------- ------------------------------ ------------------------- -------------- ------- -------- ---------- ---------- ----------------------
  *BBS2*      AR                 RP237            chr16             56536626             c.899A\>G               p.D300G                 Het         PoD                            D                         0.992          5.920   1/2184   1/314      0/384      Novel
                                                  chr16             56530975             c.1814C\>G              p.S605\*                Het         \-                             \-                        1.000          5.120   1/2184   1/314      0/384      Novel
                                 RP240            chr16             56518732             c.2107C\>T              p.R703\*                Homo        \-                             \-                        0.992          5.300   NA       1/314      0/384      Deveault et al. 2011
  *INPP5E*    AR                 RP374            chr9              139327693            c.1073C\>T              p.P358L                 Het         PrD                            D                         0.955          4.870   NA       1/314      0/384      Novel
                                                  chr9              139324862            c.1669C\>T              p.R557C                 Het         PrD                            D                         0.999          5.010   NA       1/314      0/384      Novel
  *CACNA1F*   XL                 RP401            chrX              49071594             c.3582C\>G              p.Y1194\*               Hemi        \-                             \-                        0.999          1.720   NA       1/205^†^   0/274^‡^   Novel
                                 RP403            chrX              49061832             c.5704-5C\>G            Splicing defect         Hemi        SSA                            \-                        0.480          3.150   NA       1/205^†^   0/274^‡^   Novel

Note: \#, These variants were absent from the Exome Variant Server database and were evaluated in 2184 alleles of autosome from 1000 Genome database. †, In the 157 patients, 109 are male and 48 are female, and there are 205 alleles for genes on the X chromosome. ‡, In the 327 controls, 175 are male and 152 are female, and there are 479 alleles for genes on the X chromosome. The following abbreviations are used: AR, autosomal recessive; AD, autosomal dominate; XL, X-linked; P/SS, Polyphen-2/Splice Site Prediction; 1000 G, 1000 Genome; NC, normal control; Het, heterozygous; Hom, homozygous; Hemi, hemizygous; PrD, probably damaging; PoD, possibly damaging; D, damaging; SSA, splicing site abolished;, not applicable.

Clinical data of the five patients with RP are summarized in [Table 2](#t2){ref-type="table"}. Ocular signs and symptoms in all five patients met the diagnosis of RP ([Figure 2](#f2){ref-type="fig"}). Two patients (RP237 and RP240) had *BBS2* mutations; one had RP alone with a missense mutation and a nonsense mutation, while the other one had BBS syndrome (misdiagnosed as RP) and a homozygous nonsense mutation. The patient (RP374) with *INPP5E* mutations had typical RP but without noticeable extraocular or systemic anomalies (unfortunately, a brain CT scan was not available). The two patients (RP401 and RP403) with *CACNA1F* truncation mutations showed generalized retinal degeneration involving both rods and cones.

###### Clinical features of the five patients with mutations identified in this study.

  **Patient** **ID**   **Gene**    **Variations**                 **Inheri-** **tance**   **Gender**   **Age at**   **First** **symptom**   **Visual acuity**   **Fundus** **examination**   **Electroretinography responses**   **Other** **systemic symptom**                    
  -------------------- ----------- ------------------------------ ----------------------- ------------ ------------ ----------------------- ------------------- ---------------------------- ----------------------------------- -------------------------------- ---------------- -----------------------------------------
  RP237                *BBS2*      c.\[899A\>G(;) 1814C\>G\]      Sporadic                F            14           EC                      PV; NB              0.1/0.1                      ARA; PBSL                           Extinguished                     Extinguished     None
  RP240                *BBS2*      c.\[2107C\>T\]; \[2107C\>T\]   Sporadic                M            13           7                       PV; NB              0.1/0.2                      ARA; SP                             Extinguished                     Extinguished     Polydactyly; Obesity; Diabetes mellitus
  RP374                *INPP5E*    c.\[1073C\>T\]; \[1669C\>T\]   Sporadic                F            20           EC                      PV; NB              0.2/0.2                      ARA; TLP; PBSL                      Extinguished                     Extinguished     None
  RP401                *CACNA1F*   c.\[3582C\>G\];\[ 0\]          Sporadic                M            9            NA                      PV                  0.2/0.08                     PD                                  Extinguished                     Extinguished     None
  RP403                *CACNA1F*   c.\[5704--5C\>G\];\[0\]        Sporadic                M            32           22                      PV                  0.2/0.3                      ARA; PBSL                           Severe reduced                   Severe reduced   None

Note: M, male; F, female; EC, early childhood; OD, right eye; OS, left eye; PV, poor vision; NB, night blindness; ARA, attenuated retinal arteries; PD, pigment deposit; PBSL, pigment bone spicule-like; TLR, tapetal-like retinal degeneration.

![Fundus photographs of five patients with the mutations identified in this study. The corresponding patient identification numbers and gene mutations are listed above each photo. Further clinical information about these patients is listed in [Table 2](#t2){ref-type="table"}.](mv-v21-477-f2){#f2}

Discussion
==========

Seven putative pathogenic mutations in 3 of the 129 genes known to associate with other forms of retinal dystrophy have been detected in 5 of 157 (3%, [Figure 3](#f3){ref-type="fig"}) patients with RP based on whole exome sequencing. These mutations are predicted to be causative based on bioinformatics analysis and comparison with previously reported mutations in *BBS2*, *INPP5E,* and *CACNA1F*. Ocular changes in the five patients with mutations are consistent with RP ([Figure 2](#f2){ref-type="fig"} and [Table 2](#t2){ref-type="table"}). These findings suggest that a small portion of RP may be caused by mutations in genes responsible for other forms of retinal dystrophy.

![Proportions of mutations in 129 genes associated with other forms of retinal dystrophy in 157 unrelated patients with retinitis pigmentosa.](mv-v21-477-f3){#f3}

Systematic analysis of genes responsible for other forms of retinal dystrophy in patients with RP has been limited. Previously, genotyping microarrays were used to analyze all known mutations in several genes associated with retinal dystrophy in patients with retinal dystrophy \[[@r23]-[@r25]\]. However, only a small subset of known mutations are covered by this technology, and the total diagnostic rate is less than 15% \[[@r26],[@r27]\]. Systematic analysis of most of these genes in patients with RP or hereditary retinal dystrophies has been conducted using targeted-capture sequencing. The frequencies of detected mutations in these genes are from 4% to 11% \[[@r13],[@r28],[@r29]\]. Analysis of individual genes also revealed that mutations in a few genes known to associate with other forms of retinal dystrophy also cause a fraction of RP \[[@r12],[@r30],[@r31]\]. This suggests that the frequency of mutations in genes associated with other forms of retinal dystrophy in our cohort of RP is close to that reported previously.

Consistencies and inconsistencies were both evident in the associations between the phenotypes and the identified mutations in the five patients. The two patients with *BBS2* mutations included one with nonsyndromic RP that has missense and nonsense mutations, while the other with Bardet-Biedl syndrome had a homozygous nonsense mutation. A missense and a nonsense mutation in *BBS2* have previously been reported to be responsible for Bardet-Biedl syndrome \[[@r32],[@r33]\], and two missense mutations in *BBS2* have been described recently in patients with nonsyndromic RP \[[@r34]\]. Comparisons of these findings suggest that the phenotypes might be affected by the type of mutation. Further study is needed to clarify this interesting issue.

The patient (RP374) with *INPP5E* mutations had no other noticeable signs of systemic anomalies, although mutations in *INPP5E* have been identified in patients with MORM syndrome \[[@r35]\] and Joubert syndrome \[[@r36]\]. Unexpectedly, two patients (RP401 and RP403) with RP had hemizygous truncation mutations in *CACNA1F*; these kinds of mutations have been identified in patients with congenital stationary night blindness \[[@r37],[@r38]\], cone-rod dystrophy \[[@r39]\], and Aland Island eye disease \[[@r40]\], but not in patients with RP. The association of *CACNA1F* mutations with RP in these two patients is uncertain, although the phenotype in the patients is consistent with RP, and mutations in *CACNA1F* are predicted to be null.

Overall, mutations in all known genes---including these 129 genes associated with other forms of retinal dystrophy, 72 genes related to RP and LCA, and *CHM*---could be identified in less than 58% of 157 patients with RP. In each of the disease categories, mutations were detected in 71% (24/34) autosomal dominant RP, 48% (13/27) autosomal recessive RP, 80% (8/10) X-linked RP, and 53% (46/86) sporadic RP. Over 42% of the patients without identified mutations might carry other pathogenic variants in the noncoding regions of the corresponding genes, or may have gross deletion involving whole exons that might be missed by whole exome sequencing and Sanger sequencing, or may be caused by mutations in novel genes yet to be identified. The information about these patients without identified mutations is a valuable resource for seeking out new genes that are responsible for RP.
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